March Altus Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$12.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$11.6M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$10.8M |
| 4 |
Align Technology
ALGN
|
+$10.4M |
| 5 |
Humana
HUM
|
+$8.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$13.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$13M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$12.2M |
| 4 |
Biogen
BIIB
|
+$10.9M |
| 5 |
ACOR
Acorda Therapeutics
ACOR
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.88% |
| 2 | Miscellaneous | 2.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
HCA Healthcare
HCA
$92.4B
| – | – |
-144,586
| Closed | -$10.2M |
|
|
27
Johnson & Johnson
JNJ
$640B
| – | – |
-122,361
| Closed | -$13M |
|
28
Perrigo
PRGO
$1.9B
| – | – |
-67,052
| Closed | -$10.1M |
|
29
ResMed
RMD
$31.5B
| – | – |
-87,335
| Closed | -$4.3M |
|
|
ACOR
30
DELISTED
Acorda Therapeutics
ACOR
| – | – |
-2,529
| Closed | -$10.3M |
|
|
LMNX
31
DELISTED
Luminex Corp
LMNX
| – | – |
-10,000
| Closed | -$195K |
|
|
MNTA
32
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-103,729
| Closed | -$1.18M |
|
|
ZLTQ
33
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| – | – |
-538,390
| Closed | -$12.2M |
|
|
AEGR
34
DELISTED
Aegerion Pharmaceuticals
AEGR
| – | – |
-403,054
| Closed | -$13.5M |
|
Similar funds
March Altus Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, March Altus Capital Management held 34 positions worth $219M, down 13% from $251M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
March Altus Capital Management withdrew a net $58.2M in Q4 2014, closing 11 positions and reducing 10 holdings. Its most notable exit was Aegerion Pharmaceuticals, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, March Altus Capital Management opened a new position in Amgen worth $12.8M.
- March Altus Capital Management's largest Q4 2014 buy was Amgen: 80,600 shares worth $12.8M.
- March Altus Capital Management added most to West Pharmaceutical in Q4 2014, an estimated $3.61M increase.
- March Altus Capital Management's biggest Q4 2014 reduction was Encompass Health, cutting an estimated $9.59M.
- March Altus Capital Management fully exited Aegerion Pharmaceuticals in Q4 2014, selling an estimated $13.5M.
- March Altus Capital Management's ten largest holdings make up 59% of its $219M portfolio in Q4 2014.
- March Altus Capital Management opened 9 new positions and closed 11 in Q4 2014.
- March Altus Capital Management's portfolio value fell 13% quarter-over-quarter to $219M.
Based on March Altus Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.